Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2015-10-14 AGM Information
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
FORM 6-K
AGM Information Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Redhill Biopharma Ltd., with the SEC. It contains a Notice to Shareholders regarding amendments to the Proxy Statement and Notice for the upcoming Annual General Meeting (AGM) scheduled for October 29, 2015. The content focuses on correcting a typographical error in the proxy statement and clarifying voting procedures for shareholders. There is no financial data, earnings information, or detailed report content. The document is essentially an announcement related to AGM materials, specifically the proxy statement and notice amendments. Given the nature of the content—notice and proxy statement amendments for an AGM—the most appropriate classification is AGM Information (AGM-R). The document length is under 5,000 characters and it is not a report publication announcement but a substantive notice related to the AGM.
2015-10-14 English
FORM 6-K
AGM Information Classification · 100% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It contains a proxy statement and proxy card related to the upcoming Annual General Meeting (AGM) of shareholders. The content includes details about the AGM date, agenda items such as appointment of auditors and re-election of directors, voting instructions, and shareholder rights. It also explicitly states it is a proxy statement for the AGM. There is no full financial report or earnings data presented, only information related to the AGM and proxy solicitation. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including proxy statements and notices.
2015-09-30 English
FORM 6-K
AGM Information Classification · 95% confidence The document is a Form 6-K filed by Redhill Biopharma Ltd. It contains a notice of the Annual General Meeting (AGM) of shareholders, including the meeting date, agenda items such as discussion of financial statements, appointment of auditors, and re-election of board members. The document explicitly states it is a notice of the AGM and includes proxy statement availability information. The document length is 4400 characters, which is relatively short and consistent with an announcement rather than a full report. There is no detailed financial data or comprehensive report content. Therefore, this document is best classified as AGM Information (AGM-R), which covers presentations and materials shared during the AGM or notices related to it.
2015-09-21 English
FORM 20-F/A
Annual Report FY 2014
2015-09-10 English
FORM 6-K/A
Regulatory Filings Classification · 95% confidence The document is a Form 6-K/A, which is an amendment to a previously filed Form 6-K. Form 6-K is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. The document includes an amendment to a previously filed report, specifically addressing confidential treatment requests and re-filing an exhibit. It does not contain financial statements or detailed financial analysis, nor is it an annual or quarterly report. It is a regulatory filing providing updated information to the SEC. Given the nature of the document as an amended regulatory submission without substantive financial data or report content, it fits best under Regulatory Filings (RNS). The document length is under 5,000 characters and it is an amendment notice, not the report itself.
2015-09-10 English
FORM 6-K FILING DOCUMENT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC. It contains a press release about a marketing authorization application approval under the European Decentralized Procedure. The document is relatively short (2362 characters) and primarily serves as a regulatory announcement rather than a full financial report or detailed filing. It does not contain financial statements or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2015-09-10 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.